NCT01890161View on ClinicalTrials.gov

A Phase IIa Repeat Dose AXP1275 vs Placebo Cross-over Trial With Pulmonary Allergen Challenge in Adults With Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Atopic Asthma
Interventions
DRUG

AXP1275

AXP1275 50 mg (2 × 25-mg capsules)

DRUG

AXP1275 matching placebo

AXP1275 matching placebo (2 capsules)

Trial Locations (3)

V5Z 1M9

Vancouver General Hospital, The Lung Centre, Vancouver

L8S 4K1

McMaster University, Hamilton

G1V 4G5

IUCPQ, Institut de cardiologie et de pneumologie de l'Hôpital Laval, Québec

Sponsors
All Listed Sponsors
lead

Axikin Pharmaceuticals, Inc.

INDUSTRY

NCT01890161 - A Phase IIa Repeat Dose AXP1275 vs Placebo Cross-over Trial With Pulmonary Allergen Challenge in Adults With Asthma | Biotech Hunter | Biotech Hunter